$Recro制药(REPH)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-20-138266 Act: 34 Size: 130 KB 网页链接
$Recro制药(REPH)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001564590-20-023842 Act: 34 Size: 7 MB 网页链接
$Recro制药(REPH)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-20-131095 Act: 34 Size: 36 KB 网页链接
$Recro制药(REPH)$ 内部交易: 2020-04-17,总裁 and CEO,HENWOOD GERALDINE ,卖出,80000普通股, $8.22
$Recro制药(REPH)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001192482-20-000291 Size: 9 KB 网页链接
$Recro制药(REPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001192482-20-000289 Size: 5 KB 网页链接
$Recro制药(REPH)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001564590-20-013688 Act: 34 Size: 214 KB 网页链接
$Recro制药(REPH)$ DEF 14A Other definitive proxy statements Accession Number: 0001564590-20-013681 Act: 34 Size: 933 KB 网页链接
$Recro制药(REPH)$ 8-K Current report, item 5.02 Accession Number: 0001193125-20-068813 Act: 34 Size: 17 KB 网页链接
$Recro制药(REPH)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-20-060901 Act: 33 Size: 61 KB 网页链接